Newsroom | 4257 results

CAMBRIDGE, England--(BUSINESS WIRE)--Abselion expands Amperia assay portfolio with the launch of its His-tagged Protein Quantification Kit and Sensors for recombinant protein research....

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. “It has been a productive third quarter for the Lineage team,” stated Brian...

GURUGRAM, India--(BUSINESS WIRE)--Fortis Memorial Research Institute, Gurugram, reveals success in curing children with Sickle Cell Disease through Bone Marrow transplantation....

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Cash, cash equivalents, and marketable securities: As of September 30, 2025, Arcellx had cash, cash equivalents, and marketable securities of $576.0 mi...

MINNEAPOLIS--(BUSINESS WIRE)--NMDPSM, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®), will present groundbreaking research at the 67th American Society of Hematology (ASH) Annual Meeting from Dec. 6-9 in Orlando, Fla. The data underscore NMDP’s commitment to advancing cell therapy and improving access and outcomes for all patients. Among the accepted abstracts is an oral presentation from the ACCESS clinical trial (NCT0490...

GERMANTOWN, Md.--(BUSINESS WIRE)--Amarex today announced its partnership with Britecyte, the Maryland Stem Cell Research Fund (MSCRF) $1M clinical grant awardee, to support the development of Britecyte’s Adipose Tissue Allograft (BRC-OA) for the treatment of osteoarthritis (OA), a serious and debilitating disease with unmet needs. Britecyte is collaborating with Amarex and Regenerative Orthopedics & Sports Medicine (ROSM) to determine the safety and efficacy of the BRC-OA treatment, which h...

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced new preclinical data demonstrating proof-of-concept for its in vivo, HSC-derived CAR-M, NK, and T cell platform, including its potential to durably generate lineage-restricted CAR cells in solid tumors. The data will be presented in two poster sessions this week at the Society for Immunotherapy of Cancer (SITC)...

LAS VEGAS--(BUSINESS WIRE)--Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), a Nevada-based corporation, and SGAustria Pte. Ltd. (SGAustria), a Singapore-based biotechnology company, today announced the formation of a groundbreaking Joint Venture and License Agreement aimed at revolutionizing a diabetes treatment through innovative stem cell and encapsulation technologies. The Joint Venture will now pursue a Research Collaboration Agreement (RCA) to advance a proprietary differ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced it will share two presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2025, in Orlando, Florida, including updated clinical data from iMMagine-1, its Phase 2 pivotal study (publication #25...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio announces new clinical data on its high-precision cell therapies will be presented at the 67th American Society of Hematology Annual Meeting...